Israeli phramaceutcial company BioLineRX has won FDA approval for its BL-8040 acute myeloid leukemia treatment. The drug was given orphan drug status, which is given to treatments for conditions suffered by less than 200 thousand people in the US.
Following the approval, BioLineRX will have seven years to market the drug exclusively in the US.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023

Model Sees Daylight As Boost For Hospitalized Patients’ Health
September 28, 2023

Solar Panels On A Roll Certified As Safe For Use In US, Europe
September 28, 2023

US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023
Facebook comments